GO
Loading...

Enter multiple symbols separated by commas

Search results for "TIE"

REFINE RESULTS

SEARCH RESULTS

About 90 results. Sort By: Date | Relevance
Disney shares whacked on TV business outlook

Walt Disney on Tuesday posted earnings that topped Wall Street estimates but revenue that came in below projections.
Source: CNBC.com | By: Jacob Pramuk
Drugmaker Shire bids $30B for Baxalta

Drugmaker Shire said on Tuesday it was seeking to buy Baxalta for $30 billion to forge the leading global specialist in rare diseases.
Source: Reuters
Disney shares fall on mixed earnings report

Walt Disney on Tuesday posted earnings that topped Wall Street estimates but revenue that came in below projections.
Source: CNBC.com | By: CNBC.com staff
U.S. farm, consumer groups aim to block Monsanto bid for Syngenta

Aug. 4- Several U.S. farm and consumer groups are working on strategies to derail a proposed tie-up of Monsanto Co and agricultural seeds and chemicals rival Syngenta AG, saying a combination of the market leaders would spell fewer and higher-priced products. Coalitions of opponents are being formed and market analyzes being done, moves that underscore the...
Source: Reuters | By: Carey Gillam
Uneven performances in Trump-less Republican forum

Republican candidates found themselves Trump-less in a forum Monday night, delivering strikingly uneven performances, The New York Times reports.
Source: The New York Times | By: Jeremy W. Peters and Micahel Barbaro
UPDATE 2-Drugmaker Shire bids $30 bln for Baxter spin-off Baxalta

LONDON, Aug 4- Drugmaker Shire said on Tuesday it was seeking to buy Baxalta, a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases. Shire said its unsolicited offer of 0.1687 Shire American depositary receipts per share valued each Baxalta share at $45.23. Shares in Baxalta jumped 19...
Source: Reuters | By: Paul Sandle
UPDATE 1-Shire goes public with proposed $30 bln Baxalta tie-up

LONDON, Aug 4- London- listed group Shire said it was seeking to buy Baxalta in a $30 billion all-share deal, going public with its bid to create a global specialist in rare diseases after the U.S. firm spurned its initial approach. Shire said its unsolicited offer valued each Baxalta share at $45.23. The share offer, which marks a premium of 36 percent over Baxalta's...
Source: Reuters
Shire proposes $30 bln all-share tie-up with Baxalta

LONDON, Aug 4- London- listed pharmaceutical group Shire said it was seeking to buy U.S. firm Baxalta in a $30 billion all-share deal to create a global specialist in medicines treating rare diseases with sales of $20 billion by 2020.. Shire went public with its proposal on Tuesday after Baxalta rejected the approach. Shire said it had offered to pay 0.1687 Shire...
Source: Reuters
Aetna tops 2Q profit forecasts

Aetna's second-quarter earnings jumped 33 percent and the health insurer raised its 2015 forecast again after receiving a boost from a government business it plans to feed with a $35 billion acquisition. Aetna said Thursday that higher underwriting margins or improved profitability helped balance a jump in operating costs. For the second quarter, Aetna...
Source: The Associated Press
Taste for nostalgia hits Singapore's dining scene

A new breed of modern food and beverage ventures serving up traditional fare could fortify the city-state's status as a gastronomic hub.
Source: CNBC.com | By: Nyshka Chandran